Call for Abstract

International Congress on Nosocomial and Healthcare Associated Infections, will be organized around the theme “Exploring the Challenges and Innovations in Outbreak Prevention and Control ”

NHAI 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in NHAI 2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Hospital infections are one of the major complications for health care professionals to tackle. Every day they results in prolonged hospital stays, long-term disability, and increased resistance of microbes to antimicrobials, additional costs for healthcare systems, high costs for patients and their family, and unnecessary deaths.

  • Track 1-1Infections in paediatrics and neonates
  • Track 1-2Infections in intensive care units
  • Track 1-3Infections in transplant patients
  • Track 1-4Infections in patients with renal, liver, CNS diseases
  • Track 1-5Infections in immunocompromised hosts
  • Track 1-6Infections in oncology patients
  • Track 1-7Infections in obstetrics and gynaecology patients
  • Track 1-8Infections in dialysis patients
  • Track 1-9Infections in geriatrics
  • Track 1-10Factors leading to emergence of nosocomial Infection

Medical devices are responsible for a large proportion of nosocomial infections, mainly in critically ill patients. The infections associated with the devices can cause significant medical and economic sequelae. The bacterial colonization of the indwelling device may be a prelude to both the infection and the malfunction of the device. The pathogenesis of the infections associated with the devices is centred on the multifaceted interaction of microbial, device and hosts factors.

  • Track 2-1Catheter related blood stream infection
  • Track 2-2Foreign-body and implant infections
  • Track 2-3Catheter related urinary tract infection
  • Track 2-4Innovative approaches for the prevention of device-related infections
  • Track 2-5Antiseptic-Coated Catheters

Surgical site Infection is a type of infection associated with healthcare in which a wound infection occurs after an invasive (surgical) procedure. They have a significant effect on the quality of life of the patient and are associated with significant morbidity and prolonged hospital stay. Further these infections result in considerable financial burden for health care providers.

  • Track 3-1Clinical care standards in surgery
  • Track 3-2Advances in invasive surgery to prevent infections
  • Track 3-3Measures to prevent bedsores
  • Track 3-4Complications in immunocompromised patients

A urinary tract infection is an infection relating to any part of the urinary system, including the urethra, bladder, ureters and kidneys. It is the most common type of hospital infection, among which urinary catheter infection is more frequent and caused by the urinary catheter, which is a tube inserted into the bladder through the urethra to drain the urine. 

  • Track 4-1Urinary catheter infection
  • Track 4-2Infection rate of Indwelling urethral catheter
  • Track 4-3Epidemics of nosocomial urinary tract infections

Pneumonia contracted by a patient in a hospital at least 48-72 hours after admission is known as Nosocomial pneumonia and Pneumonia associated with health risk factors such as prior hospitalization, dialysis, residing in a nursing home, immunocompromised condition is classified as a health care-associated pneumonia.

  • Track 5-1Nosocomial Pneumonia
  • Track 5-2Ventilator-Associated Pneumonia
  • Track 5-3Mycoplasma Pneumonia
  • Track 5-4Bacterial Pneumonia
  • Track 5-5Viral Pneumonia
  • Track 5-6Community-acquired pneumonia

Blood Infections or Bacteraemia or Sepsis occurs when a bacterial infection occur somewhere else in the body such as in the lungs or skin which enters the blood stream. This is dangerous because bacteria and their toxins can be transported through the bloodstream to the entire body.

  • Track 6-1Emerging blood borne infections
  • Track 6-2Current and emerging infectious risks of blood transfusions
  • Track 6-3Latest blood culture and sensitivity report
  • Track 6-4Bacteria colonization and cross contamination

Opportunistic infection is an infection caused by pathogens like bacteria, viruses, fungi or protozoa that take advantage of an opportunity that is not normally available such as a host with a weakened immune system, a modified micro biota (like disturbed Intestinal flora) or violated the integumentary barriers. Many of these pathogens do not cause disease in a healthy host that is a normal immune system. However, a compromised immune system, penetrating injury or lack of competition from normal commensals presents an opportunity for the pathogen to infect.

  • Track 7-1Virulence factors of the human opportunistic pathogen
  • Track 7-2Role of comorbidities in contracting infection
  • Track 7-3Infectious exposures to avoid
  • Track 7-4Current options and advances in treatment of opportunistic infections
  • Track 7-5Emerging opportunistic human pathogens

Emerging infectious diseases are caused by newly recognized species or strains (such as Severe Acute Respiratory Syndrome, HIV / AIDS) that may have evolved from a known infection (such as influenza) or spread to a new population (Such as West Nile fever) or undergoing ecological transformation (such as Lyme disease) or re-emerging infections, such as drug-resistant tuberculosis. Nosocomial infections caused by methicillin-resistant Staphylococcus aureus are emerging in hospitals and are extremely difficult to treat as they are resistant to many antibiotics. Many emerging diseases are zoonotic - an animal reservoir incubates the body with only intermittent transmission in human populations.

  • Track 8-1Bacterial infections: Gram-negative
  • Track 8-2Extended spectrum beta lactamase producing enterobacteriaceae
  • Track 8-3Multidrug resistant pseudomonas aeruginosa and clostridium difficile
  • Track 8-4Vancomycin resistant enterococci
  • Track 8-5Methicillin resistant Staphylococcus aureus
  • Track 8-6Multidrug resistant tuberculosis
  • Track 8-7Malarial drug resistance
  • Track 8-8Zoonotic infections
  • Track 8-9Fungal infections
  • Track 8-10Viral infections
  • Track 8-11Bacterial infections: Gram-positive
  • Track 8-12Carbapenemase producing enterobacteriaceae

Antibiotics are one of the most important therapeutic discoveries in the history of medicine. They have revolutionized the way we treat patients with infections and help reduce mortality and morbidity. Unfortunately, antibiotics are more likely to be misused. They are often unnecessarily prescribed for viral infections, against which they have no effect. Not only antibiotics, other antivirals and antimicrobials are losing their effectiveness due to their irrational use and causing antimicrobial resistance.

  • Track 9-1Novel antibiotics, spectrum of activity and their applications
  • Track 9-2Clinical and Economic Outcomes of Antimicrobial Stewardship Programs
  • Track 9-3Optimizing antibiotic usage in hospitals
  • Track 9-4Antibiotic susceptibility testing
  • Track 9-5Monoclonal antibody as an anti-infective
  • Track 9-6Antibiotic Heterogeneity And Antibiotic Cycling
  • Track 9-7Pharmacokinetics and pharmacodynamics
  • Track 9-8Antibiotic use and its relation to the emergence of resistant bacteria
  • Track 9-9Antimicrobial Stewardship
  • Track 9-10Chemotherapy

Microbial Pathogenesis reviews about the molecular and cellular mechanisms of infectious diseases. It covers microbiology, host-pathogen interaction and immunology related to infectious agents. Antimicrobial resistance refers to the natural ability of microbes to evolve genetically to counter medications. The misuse of antibiotics leads to the appearance and selection of resistant bacteria. Now the whole world is facing situation where infected patients cannot be treated effectively because the responsible bacterium is totally resistant to the antibiotics available.

  • Track 10-1Infections and resistance mechanisms of pathogens
  • Track 10-2Microbial evolution and co-adaptation
  • Track 10-3Bacterial infectivity, pathogenicity, virulence
  • Track 10-4Host- pathogen specificity, susceptibility and resistance
  • Track 10-5Immunology of Infectious Diseases
  • Track 10-6Evolving microbes and resistant infections
  • Track 10-7Genetic and physiological adaptation to the host
  • Track 10-8Prevalence of Multidrug-Resistant Organisms
  • Track 10-9Emerging issues in antibiotic resistance
  • Track 10-10Surveillance of antimicrobial use and resistance
  • Track 10-11Community-acquired infections in adults, including clinical trials

Infection control concerns the prevention of nosocomial and healthcare acquired infections. These infections are often caused by violations of infection control practices and procedures, contaminated and non-sterile surfaces or by sick hospital staff. It requires an integrated approach, a follow-up program that includes the following key elements as limiting the transmission of organisms between patients in direct patient care through hand washing and the use of appropriate gloves and aseptic practice, strategies for isolation, sterilization and disinfection practices, and nutrition and immunization, limiting the risk of endogenous infections minimizing invasive procedures and promoting optimal use of antimicrobials, infection surveillance, Identification and control of epidemics, prevention of infection among staff members, strengthening of patient care practices and continuous training of staff.

  • Track 11-1Surveillance of Infections
  • Track 11-2Strategies to prevent common endemic nosocomial infections
  • Track 11-3Hygiene Protocols
  • Track 11-4Detecting Emerging threats in Healthcare
  • Track 11-5Barriers to effective implementation of infection control
  • Track 11-6Indicator of Infection Control
  • Track 11-7Overall ICU infection control
  • Track 11-8Detecting emerging threats in healthcare
  • Track 11-9Continuing Staff Education
  • Track 11-10Identifying and controlling outbreak
  • Track 11-11Sterilization and Disinfection Practices
  • Track 11-12Hand Wash/Hand Hygiene
  • Track 11-13Methods designed to prevent the spread of infection

Microbial biofilms develop when microorganisms irreversibly adhere to a submerged surface and produce extracellular polymers that facilitate adhesion and provide a structural matrix. The Surface may be an inert, non-living or living tissue. Microorganisms may originate from the skin of patients or health workers, from tap water to which ports of entry are exposed, or from other sources in the environment. To better understand and control biofilms on permanent medical devices, researchers must develop reliable sampling and measurement techniques, study the role of biofilms in antimicrobial resistance, and to establish the link between biofilm contamination and infection of the patient.

  • Track 12-1Biofilm-Based Infections
  • Track 12-2Biofilm-Specific Antibiotic Resistance
  • Track 12-3Poly-Microbial Biofilms
  • Track 12-4Airway and Wound Biofilm Infections
  • Track 12-5Biomechanics In Biofilms and Infection
  • Track 12-6Diversification and Evolution in Biofilms
  • Track 12-7Biofilm-Related Medical Device Infections
  • Track 12-8Biofilm Community Ecology
  • Track 12-9Resistance and Tolerance of Biofilms to Antibiotics

Epidemiology is the "who, what, when, and where" of infectious diseases. The agents are transmitted through the air, food, insects, and some spread through person to person. Some agents occur worldwide, and others only in certain geographic areas or ecological circumstances. Every life form built its own profile vital. It is essential to discover the emergence of "new" diseases. Epidemiology helps develop the methodology to be used in clinical research studies, and  to a lesser extent, basic research in the biological sciences. Epidemiological studies involve an introduction, all the historical background, sources of surveillance data, laboratory diagnosis, the biological characteristics of the organism, mechanisms and routes of transmission, pathogenesis and immunity response the host, and finally the prevention, control and treatment. Epidemiologists with the help of the study design, data collection and statistical analysis of data, as well as the interpretation and dissemination of results that include peer review and the occasional systematic review. In this, they help implement and evaluate interventions at individual and community level

  • To prevent infection (primary prevention)
  • To prevent the development of disease (secondary prevention) and also
  • To prevent death and disability (tertiary prevention) associated with the disease
  • Track 13-1Epidemiology of Nosocomial Infections
  • Track 13-2Economic Burden
  • Track 13-3Statistics of Infection Control
  • Track 13-4Dynamics of disease transmission
  • Track 13-5Molecular Epidemiology
  • Track 13-6Outbreak investigations and disease surveillance
  • Track 13-7Factors leading to emergence of healthcare associated Infections
  • Track 13-8Epidemiological Transition
  • Track 13-9Epidemics of Emerging Infectious Diseases
  • Track 13-10Public awareness

Nosocomial infections are a major challenge for patient safety. Empirical antibiotic therapy should be based on careful clinical assessment and local epidemiological data regarding potential pathogens and antibiotic susceptibility. The chosen therapy should be effective, limit toxicity, and be the narrowest spectrum possible. The choice of antibiotic formulations parenteral, orally or topically is performed on the basis of clinical presentation (the site and severity of infection). Oral administration is preferred if possible. Antibiotic combinations should be used selectively and only for specific indications such as enterococcal endocarditis, tuberculosis and mixed infections. The doctor must decide whether antibiotic treatment is really necessary. In patients with fever, non-infectious diagnoses must be considered. Symptomatic treatment of shock, hypoventilation, and other complications should be provided, as well as broad-spectrum empiric antimicrobial therapy administration.

  • Track 14-1Evidence-Based Medicine
  • Track 14-2Combination Versus Monotherapy
  • Track 14-3Appropriate Antibiotic Selection and Adequate Dosing
  • Track 14-4Modification of Empiric Antibiotic Regimens
  • Track 14-5Research on antibiotic treatment and antibiotic de-escalation
  • Track 14-6Monoclonal Antibody as an Anti-Infective
  • Track 14-7Wound Care
  • Track 14-8Surgical Care
  • Track 14-9Medical Care
  • Track 14-10Critical Care
  • Track 14-11Current and Future Treatment of Nosocomial Infections
  • Track 14-12Advances in treatment of persistent nosocomial infections
  • Track 14-13Novel Therapeutic Strategies

A vaccine is a biological product that provides active acquired immunity to a particular disease

A vaccination is the injection of a killed or weakened organism that produces immunity against particular organism in the body.

Immunization is the process by which a person or animal is protected from disease. Vaccines cause immunization, and there are also some diseases that cause immunization after a person recovers from the disease.

  • Track 15-1Innovations in development of vaccines
  • Track 15-2Current clinical practices on vaccination
  • Track 15-3Recommendations of vaccines in immunocompromised patients
  • Track 15-4Criteria for vaccination and immunization schedule
  • Track 15-5Immune enhancement and genetic studies
  • Track 15-6Specificity and cross-reactivity
  • Track 15-7Role of vaccination in healthcare systems
  • Track 15-8Immunization of health-care workers
  • Track 15-9Current clinical practices on vaccination
  • Track 15-10Immune enhancement and genetic studies

Clinical microbiology plays a key role in individual and community health. Clinical microbiology laboratory plays essential role for the welfare of our people to analyse samples from patients and collecting data that allow the correct diagnosis to be made for victims of infectious diseases. They are sentinel events for bioterrorism and natural outbreaks of infection that threaten public health of the communities they serve. These laboratories provide vital information which guides the choice of antimicrobial therapy right for patients to infections that can be treated. They are the first to recognize the emergence of resistance to commonly used antimicrobial drugs. People working in clinical microbiology laboratories are highly trained professionals who make countless decisions every day that save lives and benefit the patients and at risk in our society.

  • Track 16-1Criteria for proper specimen collection
  • Track 16-2Microbial source tracking
  • Track 16-3Microorganisms and Bioterrorism
  • Track 16-4National, state and medical institutions preparedness to bioterrorism
  • Track 16-5Clinical and Public Health Microbiology
  • Track 16-6Sensitivity and Specificity
  • Track 16-7Biotechnological Innovations
  • Track 16-8Role in Outbreak Detection and Management
  • Track 16-9Lab Methods for Detection of Carrier State
  • Track 16-10Culture and Sensitivity tests
  • Track 16-11Biochemical and Susceptibility Testing
  • Track 16-12Clinical microbiology laboratory
  • Track 16-13Methods to Assess Newly Described Bacteria
  • Track 16-14Rapid and Accurate Diagnostic Testing and Reporting
  • Track 16-15Diagnostic public health microbiology
  • Track 16-16Technological advances in detection and management of infection

Biological agents including micro-organisms and toxins produced by living organisms, can cause health problems among workers. Influenza is an example of a biological hazard that affects a large population of workers. Occupational Health hazards results from exposure in the workplace to a physical, chemical or biological agent in such a way that his normal physiological mechanisms are affected and the health of the worker is impaired.

  • Track 17-1Identifying and handling biological agent threats
  • Track 17-2Occupational health hazards and illnesses
  • Track 17-3Microbiology of the built environment
  • Track 17-4Domestic and Indoor Microbiology
  • Track 17-5Contamination and cross contamination on hospital surfaces and medical equipment

Microbes are all over the world and in every possible environment. For example into the soil, one gram contains billions of microbes and all their related activities. Imagine the challenge to explore all the main groups of microbes found in each of the biomes of the earth given the scale of their immense diversity. So imagine the challenge of developing strategies to exploit and manipulate their activities. This is what environmental microbiology is about.

  • Track 18-1Bacterial communities in natural ecosystems
  • Track 18-2Ecological changes and virulence factors
  • Track 18-3Microbial Communication: Bacteria– Bacteria and Bacteria–Host
  • Track 18-4Global Change and Microbial Infectious Disease
  • Track 18-5Microorganisms and Metal Pollutants
  • Track 18-6Microorganisms and Organic Pollutants
  • Track 18-7Environmentally Transmitted Pathogens
  • Track 18-8Changing environment and threats
  • Track 18-9Antimicrobial resistance in the environment

Medical Microbiology deals with the body’s response towards invading microorganisms. Bacteriology, virology, mycology, parasitology, the main sub-fields of microbiology are first covered with the general concepts of cytology and physiology of different microbes, and with major pathogens of man. Microbial generations are smart enough to cause a change in their resistance patterns, opening a pathway for the development of new strategies and emerging trends in the fight against microbial infections. There has been a huge change in methods and diagnostic tools from frame of the nucleic acid to circulate biomarker studies.

  • Track 19-1Science of Microbiology
  • Track 19-2Systematic microbiology
  • Track 19-3Microbial Genetics
  • Track 19-4Evolution of biological complexity
  • Track 19-5Microbial Forensics

Pharmaceutical Microbiology includes research and development of antibiotic resistance, anti-infective agents, the use of microorganisms to detect carcinogenic activity and mutagenic in scheduled drugs, as well as the use of microorganisms in the making pharmaceutical products such as human growth hormone and insulin. It also focuses on the safety of medicines and also determines how a product will react in cases of contamination.

  • Track 20-1Microbial and Biochemical Technology
  • Track 20-2Antimicrobial Effectiveness Testing
  • Track 20-3Bacterial Endotoxin Testing
  • Track 20-4Microbial Examination of Non-Sterile Products
  • Track 20-5Microbes and Environmental Management
  • Track 20-6Strategies to prevent microbial contamination
  • Track 20-7Sterile Pharmaceutical Manufacturing
  • Track 20-8Wastewater treatment and bio solids reuse

Clinical studies help invent new treatment methods that help provide effective treatment. Case reports on infectious diseases include research, biology, epidemiology and clinical aspects of all diseases related to infection

  • Track 21-1Incidence and Prevalence
  • Track 21-2Morbidity and Mortality
  • Track 21-3Statistics of Infection Control
  • Track 21-4Infection rate

Health professionals and specialists in the field of microbial infection control, prevention and treatment can exhibit their products and make presentations on their products and research that should be useful in research work, business development and marketing.

  • Track 22-1Career & professional planning, preparation & advancement
  • Track 22-2Emerging Clinical Issues
  • Track 22-3Innovative teaching, curriculum & course design
  • Track 22-4Science communication & social media
  • Track 22-5Public outreach & informal science education
  • Track 22-6Broadening participation in infection control
  • Track 22-7Broadening participation in infection control

A platform designed to connect Entrepreneurs, Investors and Proposers worldwide. It aims to create and facilitate the most optimized and viable meeting place to engage people in global business discussions, evaluating and executing promising business ideas. An investor might be able to find the best potential investment opportunities globally, which provide a good return on investment. For entrepreneurs, it would be a great place to find investors and appropriate partners to start and expand their business. Thus, it is an ideal place to connect entrepreneurs, business owners, start-up companies and established companies with domestic or international investors, corporate investors and potential business partners.

  • Track 23-1Marketing
  • Track 23-2Business & management of science
  • Track 23-3Collaborations and Co Ordinations

The global hospital acquired infections testing market is poised to grow at a compound annual growth rate (CAGR) of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.

The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

Estimated cost of treating resistant infections in U.S. health care system is about $21 billion to $34 billion annually

  • Track 24-1Devices, Pharmaceuticals, and Environmental Products
  • Track 24-2Diagnostic market
  • Track 24-3Hand hygiene marketing in hospitals
  • Track 24-4Drug-Device Combinations
  • Track 24-5Laboratory testing tools
  • Track 24-6Medical devices and instruments
  • Track 24-7Municipal water treatment
  • Track 24-8Drug formulation devices
  • Track 24-9Molecular diagnostics